When symptoms become side effects: Development of the side effect attribution scale (SEAS)
- Publikationstyp:
- Zeitschriftenaufsatz
- Metadaten:
-
- Autoren
- Kate MacKrill
- Rebecca Webster
- G James Rubin
- Michael Witthoeft
- Connor Silvester
- Yasaman Emad
- Keith J Petrie
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000613941200003&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.jpsychores.2020.110340
- eISSN
- 1879-1360
- Externe Identifier
- Clarivate Analytics Document Solution ID: QB1ZI
- PubMed Identifier: 33352479
- ISSN
- 0022-3999
- Zeitschrift
- JOURNAL OF PSYCHOSOMATIC RESEARCH
- Schlüsselwörter
- Side effect attribution
- Measurement
- Nocebo effect
- Artikelnummer
- ARTN 110340
- Datum der Veröffentlichung
- 2021
- Status
- Published
- Titel
- When symptoms become side effects: Development of the side effect attribution scale (SEAS)
- Sub types
- Article
- Ausgabe der Zeitschrift
- 141
Datenquelle: Web of Science (Lite)
- Andere Metadatenquellen:
-
- Autoren
- Kate MacKrill
- Rebecca Webster
- G James Rubin
- Michael Witthöft
- Connor Silvester
- Yasaman Emad
- Keith J Petrie
- DOI
- 10.1016/j.jpsychores.2020.110340
- ISSN
- 0022-3999
- Zeitschrift
- Journal of Psychosomatic Research
- Sprache
- en
- Artikelnummer
- 110340
- Paginierung
- 110340 - 110340
- Datum der Veröffentlichung
- 2021
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.jpsychores.2020.110340
- Datum der Datenerfassung
- 2021
- Titel
- When symptoms become side effects: Development of the side effect attribution scale (SEAS)
- Ausgabe der Zeitschrift
- 141
Datenquelle: Crossref
- Abstract
- <h4>Objectives</h4>Symptom misattribution is a central process in the nocebo effect but it is not accurately assessed in current side effect measures. We have developed a new measure, the Side Effect Attribution Scale (SEAS), which examines the degree to which people believe their symptoms are treatment side effects.<h4>Methods</h4>The SEAS was tested in three New Zealand studies: a vaccination sample (n = 225), patients with gout or rheumatoid arthritis (n = 102), and patients switching to a generic medicine (n = 69). The internal reliability of the scale was examined using Cronbach's alpha. To assess validity, the Side Effect Attribution Total Score and Side Effect Attribution Binary Score were related to a number of psychological measures associated with side effect reporting.<h4>Results</h4>The scale showed good internal reliability across the three studies, with Cronbach alphas ranging from 0.840 to 0.943. Analysis of the effect sizes showed that the Attribution Total Score was generally more strongly associated with nocebo responding than Attribution Binary Score. Participants had greater Side Effect Attribution Total Scores if they had higher expectations for vaccination side effects (r = 0.18, p = .028), more worry about future vaccine effects (r = 0.16, p = .046), a higher perceived sensitivity to medicines (r = 0.50, p < .001), greater anxiety (r = 0.25, p = .016), greater intentional non-adherence (r = 0.30, p = .003), greater medicine information seeking (r = 0.26, p = .010), lower trust in pharmaceutical agencies (r = -0.29, p = .026), and lower medicine efficacy beliefs (r = -0.46, p < .001).<h4>Conclusions</h4>The SEAS provides a more nuanced assessment of symptom attribution beliefs. It appears to be more sensitive measure than just a side effect total, as it is associated with a greater number of relevant psychological variables. Future research should examine the scale in other populations and settings.
- Addresses
- Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.
- Autoren
- Kate MacKrill
- Rebecca Webster
- G James Rubin
- Michael Witthöft
- Connor Silvester
- Yasaman Emad
- Keith J Petrie
- DOI
- 10.1016/j.jpsychores.2020.110340
- eISSN
- 1879-1360
- Externe Identifier
- PubMed Identifier: 33352479
- Open access
- false
- ISSN
- 0022-3999
- Zeitschrift
- Journal of psychosomatic research
- Schlüsselwörter
- Humans
- Reproducibility of Results
- Female
- Male
- Drug-Related Side Effects and Adverse Reactions
- Surveys and Questionnaires
- Sprache
- eng
- Medium
- Print-Electronic
- Online publication date
- 2020
- Paginierung
- 110340
- Datum der Veröffentlichung
- 2021
- Status
- Published
- Datum der Datenerfassung
- 2020
- Titel
- When symptoms become side effects: Development of the side effect attribution scale (SEAS).
- Sub types
- Journal Article
- Ausgabe der Zeitschrift
- 141
Datenquelle: Europe PubMed Central
- Abstract
- OBJECTIVES: Symptom misattribution is a central process in the nocebo effect but it is not accurately assessed in current side effect measures. We have developed a new measure, the Side Effect Attribution Scale (SEAS), which examines the degree to which people believe their symptoms are treatment side effects. METHODS: The SEAS was tested in three New Zealand studies: a vaccination sample (n = 225), patients with gout or rheumatoid arthritis (n = 102), and patients switching to a generic medicine (n = 69). The internal reliability of the scale was examined using Cronbach's alpha. To assess validity, the Side Effect Attribution Total Score and Side Effect Attribution Binary Score were related to a number of psychological measures associated with side effect reporting. RESULTS: The scale showed good internal reliability across the three studies, with Cronbach alphas ranging from 0.840 to 0.943. Analysis of the effect sizes showed that the Attribution Total Score was generally more strongly associated with nocebo responding than Attribution Binary Score. Participants had greater Side Effect Attribution Total Scores if they had higher expectations for vaccination side effects (r = 0.18, p = .028), more worry about future vaccine effects (r = 0.16, p = .046), a higher perceived sensitivity to medicines (r = 0.50, p < .001), greater anxiety (r = 0.25, p = .016), greater intentional non-adherence (r = 0.30, p = .003), greater medicine information seeking (r = 0.26, p = .010), lower trust in pharmaceutical agencies (r = -0.29, p = .026), and lower medicine efficacy beliefs (r = -0.46, p < .001). CONCLUSIONS: The SEAS provides a more nuanced assessment of symptom attribution beliefs. It appears to be more sensitive measure than just a side effect total, as it is associated with a greater number of relevant psychological variables. Future research should examine the scale in other populations and settings.
- Date of acceptance
- 2020
- Autoren
- Kate MacKrill
- Rebecca Webster
- G James Rubin
- Michael Witthöft
- Connor Silvester
- Yasaman Emad
- Keith J Petrie
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/33352479
- DOI
- 10.1016/j.jpsychores.2020.110340
- eISSN
- 1879-1360
- Zeitschrift
- J Psychosom Res
- Schlüsselwörter
- Measurement
- Nocebo effect
- Side effect attribution
- Drug-Related Side Effects and Adverse Reactions
- Female
- Humans
- Male
- Reproducibility of Results
- Surveys and Questionnaires
- Sprache
- eng
- Country
- England
- Paginierung
- 110340
- PII
- S0022-3999(20)30902-8
- Datum der Veröffentlichung
- 2021
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2021
- Titel
- When symptoms become side effects: Development of the side effect attribution scale (SEAS).
- Sub types
- Journal Article
- Ausgabe der Zeitschrift
- 141
Datenquelle: PubMed
- Beziehungen:
- Eigentum von